Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 16-98 / BIG 2-97 

Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years

DESIGN

Design Trial 16-98

Results & Publications


Presentations


Posters


Publications

Study Chairs
Dr. Hervé Bonnefoi - Genève, Switzerland
Prof. Alan Coates - Centennial Park, Australia

Lead Trial Coordinator
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg16@fstrf.org

Date of Activation
May 1998

Date of Closure
August 31, 2001

Targeted Accrual
4400 patients

Final Accrual
4742 patients


Results Publications Results & Publications


News

18.03.2017:
The next IBCSG Annual Meeting will take place in Vienna, Austria on March 18 and 19, 2017 .

15.03.2017:
15th St.Gallen International Breast Cancer Conference 15-18 March 2017 in Vienna/Austria  

30.09.2016:
Benefiz-Gala mit Spitzenkoch Anton Mosimann Freitag 30. September 2016 im Park Hyatt

All News

 
  Print